24798 Federal Register / Vol. 61, No. 96 / Thursday, May 16, 1996 / Notices

Approved: May 10, 1996.

Stephen D. Potts,

Director, Office of Government Ethics.

[FR Doc. 96–12222 Filed 5–15–96; 8:45 am]

BILLING CODE 6345–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Commission on Dietary Supplement

Labels: Meeting No. 4; Opportunity To

Provide Comments

AGENCY: Office of Disease Prevention

and Health Promotion.

ACTION: Commission on Dietary

Supplement Labels: Notice of meeting

#4; Opportunity to provide comments.

SUMMARY: The Department of Health and

Human Services (HHS) is (a) providing

notice of the fourth meeting of the

Commission on Dietary Supplement

Labels, and (b) soliciting oral and

written comments.

DATES: (1) The Commission will meet

June 6, 1996, from 8:30 a.m. to 4:30 p.m.

Eastern Daylight Time at the Clarion

Plaza Hotel, 9700 International Drive,

Orlando, Florida 32819–8114; (2)

Written comments on the scope and

intent of the Commission’s objectives

may be submitted by 5:00 p.m. E.D.T. on

June 30, 1996 to the address noted

below.

FOR FURTHER INFORMATION CONTACT:

Kenneth D. Fisher, Ph.D., Executive

Director, Commission on Dietary

Supplement Labels, Office of Disease

Prevention and Health Promotion, Room

738G, Hubert Humphrey Building, 200

Independence Ave. S.W., Washington,

D.C. 20201, (202) 690–7102.

SUPPLEMENTARY INFORMATION:

Commission’s Task

Public Law 103–417, Section 12,

authorized the establishment of a

Commission on Dietary Supplement

Labels whose seven members have been

appointed by the President. The

appointments to the Commission by the

President and the establishment of the

Commission by the Secretary of Health

and Human Services reflect the

commitment of the President and the

Secretary to the development of a sound

and consistent regulatory policy on

labeling of dietary supplements.

The Commission is charged with

conducting a study and providing

recommendations for regulation of label

claims and statements for dietary

supplements, including the use of

supplemental literature in connection

with their sale and, in addition,

procedures for evaluation of label

claims. The Commission is expected to

evaluate how best to provide truthful,

scientifically valid, and nonmisleading

information to consumers in order that

they may make informed health care

choices for themselves and their

families. The Commission’s study report

may include recommendations on

legislation, if appropriate and necessary.

Announcement of Meeting

The Commission’s fourth meeting will

be June 6, 1996, 8:30 a.m. to 4:30 p.m.

Eastern Daylight Time. The meeting will

be held in the Salon Room at the Clarion

Plaza Hotel, 9700 International Drive,

Orlando, Florida 32819–8114. The

agenda will include (a) oral comments

from interested parties and the general

public, (b) identification of additional

information needs, and (c) discussion of

dietary supplement label information.

Public Participation at Meeting

The meeting is open to the public.

However, space is limited. Both oral and

written comments from the public will

be accepted, but oral comments at the

meeting will be limited to a maximum

of five minutes per presenter; thus,

organizations and persons wishing to

make their views known to the

Commission should use the time for oral

presentation to summarize their written

comments. Persons and organizations

that have not made presentations or

submitted statements previously will be

given preference on the agenda.

Members of the Commission may wish

to question the presenters following

each oral presentation. Please request

the opportunity to present oral

comments in writing and provide fifteen

(15) copies of the written comments

from which the oral presentation is

abstracted to the address above by May

29, 1996. If you will require a sign

language interpreter, please call Sandra

Saunders (202) 690–7102 by 4:30 p.m.

E.D.T. on May 29, 1996.

Written Comments

By this notice, the Commission is

soliciting submissions of written

comments, views, information, and data

pertinent to the Commission’s task.

Comments should be sent to Kenneth D.

Fisher, Ph.D., Executive Director of the

Commission at the Office of Disease

Prevention and Health Promotion, Room

738G, Hubert Humphrey Building, 200

Independence Ave. S.W., Washington,

D.C. 20201, by 5:00 p.m. E.D.T. on June

30, 1996.

Dated: May 8, 1996.

Claude Earl Fox,

Deputy Assistant Secretary for Health

(Disease Prevention and Health Promotion),

Department of Health and Human Services.

[FR Doc. 96–12223 Filed 5–15–96; 8:45 am]

BILLING CODE 4160–17–M

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that

the Office of Research Integrity (ORI)

has made final findings of scientific

misconduct in the following case:

Michael W. Washabaugh, Ph.D., Johns

Hopkins University: Based on an

investigation conducted by the

institution as well as information

obtained by ORI during its oversight

review, ORI found that Michael W.

Washabaugh, Ph.D., Associate Professor

of Biochemistry, Department of

Biochemistry, Johns Hopkins University

School of Hygiene and Public Health,

committed scientific misconduct by

reporting falsified and/or fabricated

research data in two grant applications

submitted to the National Institutes of

Health.

Specifically, Dr. Washabaugh (1)

reported falsified results of experiments

concerning the number of DTNB (5,5′-

dithiobis [2-nitrobenzoate]) reactive

thiols in native thiamin binding protein

in a grant application entitled

‘‘Mechanism of a periplasmic

permease,’’ and (2) reported falsified

and/or fabricated portions of data

presented in two separate figures to

support his hypothesis of thiamin

binding to thiamin binding protein in

grant applications entitled ‘‘Mechanism

of a periplasmic permease’’ and

‘‘Mechanisms of enzymic and nonenzymic thiamin reactions.’’

Dr. Washabaugh has entered into a

Voluntary Exclusion Agreement with

ORI in which he has voluntarily agreed,

for the four (4) year period beginning

May 7, 1996, to exclude himself from:

(1) Any contracting or subcontracting

with any agency of the United States

Government and from eligibility for, or

involvement in, nonprocurement

transactions (e.g., grants and cooperative

agreements) of the United States

Government as defined in 45 C.F.R. Part

76 (Debarment Regulations), and

(2) Serving in any advisory capacity to

the Public Health Service (PHS),

including but not limited to service on

any PHS advisory committee, board,

and/or peer review committee, or as a

consultant.